Hemanext

Hemanext is a Lexington, Massachusetts medical technology company that reengineers how donated red blood cells are stored. Its flagship system, Hemanext ONE, removes oxygen and carbon dioxide from red blood cell units during processing and keeps the environment hypoxic through 42 days of refrigerated storage, slowing the oxidative degradation known as the storage lesion. The system carries FDA marketing authorization (originally via the De Novo pathway) and a CE mark, and aims to deliver a higher-quality blood product for patients who depend on transfusion, including those with thalassemia, sickle cell disease, and trauma.